DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 148 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,167,035 | +72.4% | 91,748 | +122.1% | 0.01% | +75.0% |
| Q4 2022 | $676,973 | -10.8% | 41,304 | +0.7% | 0.00% | -20.0% |
| Q3 2022 | $759,000 | -46.7% | 41,037 | -62.1% | 0.01% | -44.4% |
| Q2 2022 | $1,423,000 | +25.7% | 108,221 | -11.4% | 0.01% | +50.0% |
| Q1 2022 | $1,132,000 | +40.8% | 122,142 | +48.4% | 0.01% | +50.0% |
| Q4 2021 | $804,000 | +9.7% | 82,326 | +281.7% | 0.00% | 0.0% |
| Q3 2021 | $733,000 | +47.5% | 21,566 | +58.9% | 0.00% | +33.3% |
| Q2 2021 | $497,000 | +262.8% | 13,573 | +343.1% | 0.00% | +200.0% |
| Q1 2021 | $137,000 | -71.8% | 3,063 | -64.0% | 0.00% | -66.7% |
| Q4 2020 | $485,000 | +11.2% | 8,500 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $436,000 | -76.8% | 8,500 | -73.0% | 0.00% | -75.0% |
| Q2 2020 | $1,883,000 | +45.1% | 31,531 | 0.0% | 0.01% | +33.3% |
| Q1 2020 | $1,298,000 | – | 31,531 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |